IARC and CeHDI launch collaboration to advance equity in HPV vaccine innovation

The International Agency for Research on Cancer (IARC) and the Global Center for Health Diplomacy and Inclusion (CeHDI) have launched a new collaboration to advance equity in cervical cancer prevention. A recently signed agreement supports a joint project focused on generating evidence to inform the development of next-generation human papillomavirus (HPV) vaccines.

The project, Advancing Inclusion of HPV 35 Genotype into New-Generation HPV Vaccines, is being implemented from November 2025 until May 2026. It aims to clarify the burden of HPV 35, as emerging evidence suggests a high prevalence in several sub-Saharan African settings, through systematic literature reviews. It will also assess the potential added benefit of incorporating this genotype into future vaccine formulations, using impact modelling.

The findings will contribute to ongoing global discussions on HPV vaccine innovation and help ensure that forthcoming multivalent HPV vaccines respond to regional disease patterns and promote greater health equity.

This collaboration reflects the shared commitment of IARC, CeHDI, and the World Health Organization (WHO) to supporting scientific evidence that advances the WHO Cervical Cancer Elimination Initiative and strengthens prevention options for all populations, especially those who are currently underserved.

View photo of the first Scientific Advisory Group meeting